NewLink Genetics (NASDAQ:NLNK) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

A number of other brokerages have also recently commented on NLNK. Robert W. Baird raised NewLink Genetics from a “neutral” rating to an “outperform” rating and upped their price target for the company from $8.00 to $22.00 in a research report on Friday, September 8th. ValuEngine raised NewLink Genetics from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 7th. Stifel Nicolaus upped their price target on NewLink Genetics from $14.00 to $29.00 and gave the company a “buy” rating in a research report on Monday, September 11th. Bank of America started coverage on NewLink Genetics in a research report on Friday, October 13th. They set a “buy” rating and a $22.00 price target on the stock. Finally, Jefferies Group dropped their price target on NewLink Genetics from $26.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. NewLink Genetics has an average rating of “Buy” and a consensus target price of $23.29.

NewLink Genetics (NLNK) traded down $1.06 during mid-day trading on Friday, reaching $9.00. The company’s stock had a trading volume of 1,846,500 shares, compared to its average volume of 1,564,400. NewLink Genetics has a twelve month low of $5.90 and a twelve month high of $25.17. The stock has a market capitalization of $326.00, a PE ratio of -3.69 and a beta of 1.10.

Several hedge funds and other institutional investors have recently modified their holdings of NLNK. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of NewLink Genetics by 1,823.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,269 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 9,735 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of NewLink Genetics during the 3rd quarter valued at $114,000. State of Wisconsin Investment Board purchased a new stake in NewLink Genetics during the 2nd quarter worth about $125,000. Advisor Group Inc. lifted its holdings in NewLink Genetics by 3.4% during the 2nd quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 600 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in NewLink Genetics by 3.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 556 shares in the last quarter. 52.63% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “NewLink Genetics (NLNK) Upgraded to “Hold” at BidaskClub” was first published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/05/newlink-genetics-nlnk-upgraded-to-hold-at-bidaskclub.html.

NewLink Genetics Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.